Korea's Cutting-Edge Biologics Law One Year On : What More Is Needed?
At a recent healthcare forum in Seoul, South Korea regenerative medicine industry executives and researchers discussed the current status of the sector, as well as what policy changes and support are needed to invigorate research, development and commercialization.
You may also be interested in...
Novartis among the first to benefit with approvals for Zolgensma, Kymriah, and Luxturna. The new law has also enabled its first clinical trial – a Phase Ib study by Seoul National University of a CAR-T therapy for recurrent or refractory, CD19-positive, B-cell acute lymphoblastic leukemia.
Only one last step remains before the approval of South Korea’s first home-grown COVID-19 vaccine as SK Bioscience’s SKYCovione (GBP510) receives positive assessments from review committees. Any nod, which could happen this week, would mark a milestone for the country's ambitions of becoming a global vaccine hub.
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.